Список проголосовавших за комментарий " On The Wires<ul><li>Soligenix (<strong>SNGX</strong>) announced that Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix will present preclinical and clinical results on the use of dusquetide (SGX94) in the treatment of emerging and antibiotic resistant infectious diseases at Superbugs & Superdrugs — A Focus on Antibacterials. The conference is being held in London March 20-21, 2017.</li><li>Corindus Vascular Robotics (<strong>CVRS</strong>) announced WakeMed Health & Hospitals purchased three CorPath GRX Systems to develop a vascular robotics program.</li><li>On Mar 14, 2017, Revance Therapeutics (<strong>RVNC</strong>) entered into a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea a contract development and manufacturing organization. Althea has agreed, among other things, to provide the co with a future source of commercial fill/finish services for the co's neuromodulator products. The services agreement provides the co expanded capacity and a second source of drug product manufacturing to support a global launch of DaxibotulinumtoxinA for Injection. The services agreement also mitigates supply chain risk by giving the Company a different manufacturing location than its current site and reduces future capital and operating expenditures required in the co's primary manufacturing facility by outsourcing to an experienced partner.</li><li>Prima BioMed (<strong>PBMD</strong>) announces that the second cohort comprising six patients has now been fully recruited for its TACTI-mel clinical trial being conducted in Australia. Patients with unresectable or metastatic melanoma that have had a suboptimal response to Keytruda were dosed with the higher 6 mg dose of IMP321 in combination with Keytruda.</li></ul>"